Slide 1: Form 6-K cover page
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2014 _______________________ BioLineRx Ltd. (Translation of Registrant’s name into English) ______________
Slide 2: Form 6-K: conference call notice
On May 20, 2014, at 10:00 am EDT, the Registrant will conduct a conference call concerning its operating results for the quarter ended March 31, 2014. The presentation with information relating to such conference call is filed as Exhibit 1 to this Report on Form 6-K. This Form 6-K, including all exh
Slide 3: Form 6-K signature page
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip Serlin Philip Serlin Chief Financial and Operating Officer Dated: May 20, 2014
Slide 4: First Quarter 2014 Earnings Presentation
First Quarter 2014 Earnings Presentation May 20, 2014
Slide 5: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u
Slide 6: Pipeline
Pre-Clinical LEAD DEVELOPMENT PROGRAMS AML Stem ca mobizatin om Pinesiaornstssuy =o ADDITIONAL DEVELOPMENT PROGRAMS BL-5010 Skin lesions BL-7040 Intlammatory bowel disease BL-9010 Severe asthma/aliergies PROGRAMS PARTNERED OR IN CO-DEVELOPMENT BL-1040 Ventricular remodeling post-AMI BL-8020 HCV and
Slide 7: Update on Operations and Lead Programs
Chief Executive Officer Kinneret Savitsky, Ph.D. Update on Operations and Lead Programs 4
Slide 8: BL-1040: First-in-class myocardial implant for prevention of ventricular remodeling following AMI
BL-1040: FIRST-IN-CLASS MYOCARDIAL IMPLANT FOR PREVENTION OF VENTRICULAR REMODELING FOLLOWING AMI • Pivotal CE Mark Registration trial progressing at full steam – Under partnership with Bellerophon (f/k/a Ikaria) – Bioabsorbable Cardiac Matrix (BCM) – Placebo controlled; ~300 patients; six-month fol
Slide 9: BL-8040: Best-in-class CXCR4 antagonist
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST Promising Platform Candidate for Hematological Cancers ü Evidence for robust apoptosis of cancer cells ü Substantial mobilization of cancer cells from bone marrow ü Strong global IP estate: 13 issued/25 patents pending worldwide (two recent in U.S) ü Received
Slide 10: BL-7010: Novel gliadin binding polymer for celiac disease
BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE Exciting progress in a fast-growing market – Significantly increased Pharma interest – Very high-need and underserved population Phase 1/2 study ongoing in celiac patients: • Dose escalation: – Reached highest planned single dose without limi
Slide 11: First Quarter 2014 Financial Overview
Chief Financial & Operating Officer Philip A. Serlin, CPA, MBA First Quarter 2014 Financial Overview 8
Slide 12: Completed Significant Financing in early 2014
Completed Significant Financing in early 2014 • Raised $24.1 million in underwritten public offering of ADS’s • Roth Capital (lead) and Maxim (co-manager) • Included 1,260,000 ADS’s granted to cover over-allotment option • Significantly oversubscribed • Broadens U.S. institutional investor base • AD
Slide 13: Financial Overview
Financial Overview (in USD at 31-Mar-14 exchange rate) • Research and development • Total R&D expenses decreased by $2.8 million, to $2.7 million in Q114 • Primarily from termination of the BL-1020 CLARITY clinical trial in March 2013 • Decrease partially offset by ramp-up in spending on lead clinic
Slide 14: Financial Overview
Financial Overview (in USD at 31-Mar-14 exchange rate) • Non-operating income • Non-operating income decreased $1.8 million, to $1.7 million in Q114 • Primarily stems from fair-value adjustment related to warrant liability • Financial income/expenses • Net financial income was $0.3 million for Q114,
Slide 15: Major Milestones over next 12 Months
Major Milestones over next 12 Months BL-8040 (SC Mobilization) phase 1 initiation BL-7010 (Celiac Disease) phase 1/2 completion BL-8040 (AML) phase 2 partial results* BL-8040 (CML) phase 1/2 study initiation BL-1040 (AMI) complete CE mark study enrollment BL-7010 (Celiac Disease) pivotal study initi
Slide 16: Thank You! Questions?
Bench1to Bedside ro Pattiner Tie _ —_ y x eer THANK YOU! QUESTIONS? BIOLINEFM ><